Catabasis Announces Appointment of Kenneth M. Bate as Independent Director - Action News 5 - Memphis, Tennessee

Catabasis Announces Appointment of Kenneth M. Bate as Independent Director

  • HealthMore>>

  • People seek out health info when famous person dies

    People seek out health info when famous person dies

    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...More >>
    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...More >>
  • Spouse's sunny outlook may be good for your health

    Spouse's sunny outlook may be good for your health

    Marriage vows often include the promise to stick together for better or for worse, and research now suggests that when it comes to your health, having an optimistic spouse is better.More >>
    Marriage vows often include the promise to stick together for better or for worse, and research now suggests that when it comes to your health, having an optimistic spouse is better.More >>
  • Mental illness not a driving force behind crime

    Mental illness not a driving force behind crime

    TUESDAY, April 22, 2014 (HealthDay News) -- Less than 10 percent of crimes committed by mentally ill people are directly linked to the symptoms of their disorders, a new study shows. "When we hear about crimes committed by people with mental illness, they tend to be big headline-making crimes, so they get stuck in people's heads," said study author Jillian Peterson, a psychology professor at Normandale Community College in Bloomington, Minn. "The vast majority of people with mental illness a...More >>
    TUESDAY, April 22, 2014 (HealthDay News) -- Less than 10 percent of crimes committed by mentally ill people are directly linked to the symptoms of their disorders, a new study shows. "When we hear about crimes committed by people with mental illness, they tend to be big headline-making crimes, so they get stuck in people's heads," said study author Jillian Peterson, a psychology professor at Normandale Community College in Bloomington, Minn. "The vast majority of people with mental illness a...More >>

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Catabasis Pharmaceuticals Inc.

CAMBRIDGE, Mass., Feb. 4, 2014 /PRNewswire/ -- Catabasis Pharmaceuticals Inc. today announced the appointment of Kenneth M. Bate to its board of directors as an independent director. Mr. Bate is an experienced biotechnology executive having led companies at various stages of development. He currently is chairman of the board of Cubist Pharmaceuticals, Inc., and is a director of BioMarin Pharmaceuticals, AVEO Pharmaceuticals and TransMedics, Inc. Mr. Bate currently serves as an independent biotechnology industry consultant and previously has served as president and chief executive officer of Archemix Corp. and NitroMed Inc., chief financial officer of Millennium Pharmaceuticals Inc. and Biogen Inc., and co-founded JSB Partners LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. He holds an MBA from the Wharton School of the University of Pennsylvania and a BA from Williams College.

"This is an important period in Catabasis' development and we are fortunate to be adding someone with Ken's breadth of experience to our board of directors," said Michael Ross, Ph.D., chairman of Catabasis' board of directors. "Ken brings a track record of building and guiding successful public and private biotechnology companies. This experience will be indispensable to Catabasis as it completes three Phase 2 trials of its lead SMART Linker conjugate CAT-2003 in hypertriglyceridemias this year, and advances additional candidates based on its SMART Linker conjugation technology in dyslipidemias and inflammatory diseases."

About Catabasis

Catabasis is a clinical-stage company dedicated to the discovery and development of innovative medicines to treat inflammatory and metabolic diseases. The company's drug development programs are rooted in the principles of pathway pharmacology, the treatment of diseases by simultaneously modulating more than one target in a disease pathway. Using its proprietary SMART Linker technology, the company conjugates two drugs that act on different components of a disease pathway with the goal of producing new chemical entities with significantly enhanced efficacy and improved safety and tolerability profiles. The company has assembled an experienced team that is passionately committed to improving the lives of patients. The company was founded in 2008 and is headquartered in Cambridge, Mass.

Please visit www.catabasis.com for more information.

Corporate Contact
Amy Lynch
Catabasis Pharmaceuticals Inc.
T: (617)-349-1971
alynch@catabasis.com

Media Contacts
Tony Russo, Ph.D.
Matt Middleman, M.D.
T: 212-845-4251
T: 212-845-4272
tony.russo@russopartnersllc.com 
matt.middleman@russopartnersllc.com

 

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow